5 Results for "

Vadadustat

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Vadadustat" in MCE Product Catalog:

9
9 Cited Publications
Cat. No.: HY-101277
CAS No.: 1000025-07-9
Purity:  99.83%
Synonyms: PG-1016548; AKB-6548
Research Areas:  

Cardiovascular Disease

Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .
loading...
    loading...
Cat. No.: HY-101277S1
Synonyms: PG-1016548-13C6; AKB-6548-13C6
Vadadustat- 13C6 (PG-1016548- 13C6) is 13C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .
loading...
    loading...
Cat. No.: HY-183654
Vadadustat prodrug-1 is a near-infrared activated photocaged, blood-brain barrier-permeable neuroprotective prodrug of Vadadustat (HY-101277). Vadadustat prodrug-1 masks the acidic pharmacophore of Vadadustat, and releases active Vadadustat upon irradiation at 650 nm to inhibit PHD2. Vadadustat prodrug-1 reduces cell damage, infarct volume and cerebral edema, and promotes neurological function recovery. Vadadustat prodrug-1 can be used for the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-101277R
CAS No.: 1000025-07-9
Synonyms: PG-1016548 (Standard); AKB-6548 (Standard)
Vadadustat (Standard) is the analytical standard of Vadadustat (HY-101277). This product is intended for research and analytical applications. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .
loading...
    loading...
Cat. No.: HY-179647
CAS No.: 1795110-22-3
ZG-2686 is a potent and selective HIF-2α agonist with an EC50 of 0.25 µM. ZG-2686 exhibits selectivity over PHD2. ZG-2686 binds to a specific internal cavity of HIF-2α, forming hydrogen bonds via structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances transcriptional activity. ZG-2686 synergizes with Vadadustat (HY-101277) to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 can be used for the research of renal anemia .
loading...
    loading...